I believe the surgiceutical approach to prevent adhesions is a gamechanger in gynecology pelvic surgeries. For me it is important that it is not a barrier or medical devices which are not that effective. Read More
Dr. James Greenberg Vice Chair Obs and Gyne, Brigham and Women's, Harvard Medical School
Endometriosis: But your tests are all negative?
Oct 26, 2020First Surgiceutical drug candidate that truly prevents formation of post-operative tissue fibrosis
TTX 330 is a therapeutic & bioresorbable polymer combination that helps reduce fibrosis in synovial joints
TTX 334e is a novel non-hormonal drug candidate being studied for the treatment of endometriosis.
TTX 334o is a novel targeted therapeutic for range of solid tumors, particularly recurrent, sensitive and platinum resistant cancers
TTX 334Dx translating a novel biomarker into the first non-invasive blood test for diagnosing endometriosis
Chairman, Previous VP International Marketing, Abbott
SVP, Corporate Business Development, Mission Pharmacal Company
Managing Director, Yorkville Advisors
Sr. Director, US Aortic Stent Graft Programs, CryoLife
CEO, Micron Biomedical, Inc.
VP, Associate General Counsel, IP, Emergent BioSolutions
Mexican Businessman and Entrepreneur
Previously CEO, Check-Cap, Ltd
Chief Financial Officer, Lineage Cell Therapeutics, Inc.
CEO
Chief Scientific Officer
Chief Medical Officer & Global Medical Lead
Chief Strategic Counsel
MD, Clinical Advisor
MD, MPH
MD, MSc, PhD
PhD, MD, FRCS
MS, PhD, FEAS, FCAHS
“The definitive diagnosis of endometriosis can only be made by histopathology showing endometrial glands and stroma with varying degree of inflammation and fibrosis.” (Rafique & Decherney, 2017); “Currently, there are no non-invasive tests available in clinical practice to accurately
Read MoreIt started early in the year. In January, a widely cited Vogue cover story on the tennis great Serena Williams, who gave birth to a daughter in September of 2017, told the harrowing tale of how Williams had to urgently insist to the hospital staff in her recovery room that what she was experiencing
Read More
“Evitar™ offers a potential therapeutic option for preventing adhesion formation based on sound scientific principles with the exciting triad of Efficacy, Safety and Ease of Use.”... Read More
Evitar™ provides a totally new pre-emptive concept, that actively intervenes in the molecular pathway of adhesion formation."... Read More
Urmonderbaan 22 (Gate 2) 6167 RD Geleen Netherlands
PO Box 18 6160 MD Geleen Netherlands
info@templerx.com
© 2020 Temple Therapeutics BV. All Rights Reserved
Website Design & Developed by 2Web Design
